[go: up one dir, main page]

NO20061245L - Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en bisfosfon - Google Patents

Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en bisfosfon

Info

Publication number
NO20061245L
NO20061245L NO20061245A NO20061245A NO20061245L NO 20061245 L NO20061245 L NO 20061245L NO 20061245 A NO20061245 A NO 20061245A NO 20061245 A NO20061245 A NO 20061245A NO 20061245 L NO20061245 L NO 20061245L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
alkylidene
vitamin
bisphosphone
derivatives
Prior art date
Application number
NO20061245A
Other languages
English (en)
Inventor
Andrew George Lee
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20061245L publication Critical patent/NO20061245L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår farmasøytiske preparater og metoder for behandling omfattende administrering til en pasient med behov for dette av en kombinasjon av et 2-alkyliden-19-nor-vitamin D-derivat og et bisfosfonat. Spesielt angår foreliggende oppfinnelse farmasøytiske preparater og metoder for behandling omfattende administrering til en pasient med behov for dette av 2-rnetylen-19-nor-20(S)-1a,25-dihydroksyvitarnin D3 og et bisfosfonat.
NO20061245A 2003-09-19 2006-03-17 Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en bisfosfon NO20061245L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50400803P 2003-09-19 2003-09-19
PCT/IB2004/002935 WO2005027921A1 (en) 2003-09-19 2004-09-06 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate

Publications (1)

Publication Number Publication Date
NO20061245L true NO20061245L (no) 2006-05-31

Family

ID=34375430

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061245A NO20061245L (no) 2003-09-19 2006-03-17 Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en bisfosfon

Country Status (16)

Country Link
US (1) US20050065117A1 (no)
EP (1) EP1667691A1 (no)
JP (1) JP2007505886A (no)
KR (1) KR20060058134A (no)
CN (1) CN1852719A (no)
AU (1) AU2004273672A1 (no)
BR (1) BRPI0414565A (no)
CA (1) CA2539359A1 (no)
IL (1) IL174216A0 (no)
MX (1) MXPA06003063A (no)
NO (1) NO20061245L (no)
NZ (1) NZ545804A (no)
RU (1) RU2326695C2 (no)
TW (1) TW200524617A (no)
WO (1) WO2005027921A1 (no)
ZA (1) ZA200602270B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
EP1798236A1 (en) * 2005-12-13 2007-06-20 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Process for the preparation of 3-pyridyl-1-hydroxyethylidene-1,1- biphosphonic acid and hydrated forms thereof
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
EA201001097A1 (ru) * 2008-03-18 2011-02-28 Александр Владимирович ДИКОВСКИЙ Фармацевтическая композиция для профилактики и лечения резорбции костной ткани различной этиологии
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TR200900878A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
TR200900880A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
EP2473172B1 (en) 2009-09-01 2015-04-08 Duke University Bisphosphonate compositions and methods for treating heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
US8859530B2 (en) 2013-03-08 2014-10-14 Voltarra Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US9012432B2 (en) * 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
IT201700031017A1 (it) * 2017-03-21 2018-09-21 Bioenx S R L Composizioni utili per il trattamento dell'alopecia androgenica comprendenti acido etidronico
EP3648797A1 (en) * 2017-07-05 2020-05-13 EPOS-Iasis Research and Development, Ltd Multifunctional conjugates
CN107550919A (zh) * 2017-09-04 2018-01-09 杭州旦承医药科技有限公司 唑来膦酸的用途及粉雾剂和制备方法
CN107441101A (zh) * 2017-09-04 2017-12-08 杭州旦承医药科技有限公司 伊班膦酸钠的用途及粉雾剂和制备方法
CN114126623A (zh) * 2019-05-17 2022-03-01 宾夕法尼亚大学董事会 治疗肥胖和/或皮肤紊乱的方法和组合物
GB202016614D0 (en) 2020-10-20 2020-12-02 King S College London Compounds
WO2023177283A1 (en) * 2022-03-14 2023-09-21 Erasmus University Medical Center Rotterdam A combination therapy for bone loss and/or muscle loss.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
IT1194748B (it) * 1981-02-12 1988-09-28 Gentili Ist Spa Composizioni farmaceutiche per il trattamento di osteopatie
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0275821B1 (de) * 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
GB9220439D0 (en) * 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
TW257765B (no) * 1993-08-25 1995-09-21 Merck & Co Inc
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
BR9810027A (pt) * 1997-06-11 2000-09-12 Procter & Gamble Comprimido revestido por pelìcula para melhorada segurança do trato gastrintestinal superior
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
ES2269014T3 (es) * 1997-07-22 2007-05-01 MERCK & CO. INC. Procedimiento para inhibir la resorcion osea.
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5843923A (en) * 1998-05-22 1998-12-01 Jame Fine Chemicals, Inc. Glucosamine sulfate potassium chloride and process of preparation thereof
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
DE19935771A1 (de) * 1999-07-23 2001-02-01 Schering Ag Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
WO2002080933A1 (en) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children A drug for use in bone grafting
RU2297229C2 (ru) * 2001-05-02 2007-04-20 Новартис Аг Фармацевтическое применение бисфосфонатов
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses

Also Published As

Publication number Publication date
IL174216A0 (en) 2006-08-01
WO2005027921A1 (en) 2005-03-31
CN1852719A (zh) 2006-10-25
JP2007505886A (ja) 2007-03-15
AU2004273672A1 (en) 2005-03-31
EP1667691A1 (en) 2006-06-14
US20050065117A1 (en) 2005-03-24
RU2006108550A (ru) 2007-09-27
CA2539359A1 (en) 2005-03-31
ZA200602270B (en) 2007-09-26
KR20060058134A (ko) 2006-05-29
BRPI0414565A (pt) 2006-11-07
RU2326695C2 (ru) 2008-06-20
MXPA06003063A (es) 2006-05-31
NZ545804A (en) 2009-09-25
TW200524617A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
NO20061245L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en bisfosfon
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20045301L (no) Substituert 1,3-diphenylprop-2-en-1-one derivat, fremstilling og anvendelse derav.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
PL2526934T4 (pl) Inhibitory kinazy tyrozynowej Brutona
GB0222495D0 (en) Compounds
NO20081844L (no) Terapeutiske forbindelser
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200611695A (en) Pyrrolopyridine derivatives
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
MXPA05010020A (es) Derivados de oxamida.
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
GB2446341A (en) Method and system for transdermal drug delivery
SE0300457D0 (sv) Novel compounds
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
NO20060655L (no) 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application